PatientsVille.com Logo

SEIZURE and Diclofenac

PatientsVille

SEIZURE Symptoms and Causes

Seizures are symptoms of a brain problem. They happen because of sudden, abnormal electrical activity in the brain. When people think of Seizures, they often think of convulsions in which a person's body shakes rapidly and uncontrollably. Not all Seizures cause convulsions. There are many types of Seizures and some have mild symptoms. Seizures fall into two main groups. Focal Seizures, also called partial Seizures, happen in just one part of the brain. Generalized Seizures are a result of abnormal activity on both sides of the brain.

Most Seizures last from 30 seconds to 2 minutes and do not cause lasting harm. However, it is a medical emergency if Seizures last longer than 5 minutes or if a person has many Seizures and does not wake up between them. Seizures can have many causes, including medicines, high fevers, head injuries and certain diseases. People who have recurring Seizures due to a brain disorder have epilepsy.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for SEIZURE

SEIZURE treatment research studies

Diclofenac clinical trials, surveys and public health registries


Find Drug Side Effect reports



Diclofenac Side Effects

Renal Failure Acute (154)
Abdominal Pain (139)
Diarrhoea (136)
Vomiting (128)
Dyspnoea (103)
Haemoglobin Decreased (103)
Gastrointestinal Haemorrhage (102)
Nausea (88)
Blood Creatinine Increased (88)
Anaemia (86)
Malaise (83)
Dehydration (82)
Pruritus (79)
Abdominal Pain Upper (77)
Blood Urea Increased (76)
Dizziness (72)
Gastric Ulcer (68)
Gastrointestinal Disorder (68)
Haematemesis (64)
Anaphylactic Reaction (62)
Pyrexia (61)
Erythema (60)
Fatigue (60)
Pain (60)
Hypotension (57)
Melaena (56)
Embolia Cutis Medicamentosa (54)
Chest Pain (54)
Arthralgia (53)
Rash (53)
Oedema Peripheral (51)
Asthenia (50)
Loss Of Consciousness (49)
Alanine Aminotransferase Increased (49)
Fall (48)
Headache (47)
Blood Alkaline Phosphatase Increased (47)
Metabolic Acidosis (46)
Gastritis (46)
Renal Failure (45)
Cardiac Arrest (44)
Confusional State (43)
Back Pain (43)
C-reactive Protein Increased (43)
Convulsion (43)
Urticaria (43)
Blood Pressure Decreased (41)
Weight Decreased (41)
Peritonitis (41)
Aspartate Aminotransferase Increased (40)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I injected diclofenac injection without any accident

Im general practioner i gave on intra mascular diclofenac for fever and body and about 8 or less he is dead inspite of using diclofeac tablet before and there is no prblem

My granddaughter has been suffering from febrile seizures every test has been done no answers what can cause an imbalance in body temp that can cause high spikes in temp that can cause seizures

What is an effective alternative to diclofenac ?

What is Diclac Gastro-resistant tablets and for what they are?

What treetment purple spot in all the body cause of diclofenac inj

A powerful CONVULSANT . NOT to be used in seizure prone individuals !

Been on this 14 monthstoo long comming off it thank god to many problems on epilim to name, i only had 1 seizure in my life at 28 and i was apparently anepilepticthey put me on tretegol after i was refered to see a neuro

Been taking Miralax for about three weeks - a capful measure each morning, to relieve painful cramping resultant from seizure medication. It gave almost instant relief for the pain; stool is very soft and almost liquid. I plan to reduce amount of M

Every time I use Vagifem I have a seizure the next day or two. I'm 64 weigh 132 very active with my horses and Real Estate. I'm dowm to using this product once a week, The Dr. wants me to useit twice a week, yea right. Nancy

Feb 17th my 7 yr old daughter had a seizure less than 45 min after getting a shot of phenegran 12.5 mg. My daughter had 2mg of zofran at 5 am and again at abot 1030 am and at 230 or so she got the shot of phenegran for nausea. Our daughter never h

Hi , My son is 5 years old and is was put on epilim for a week now , he was diagnosed with autism and attends a school for kids with autism . The reason for the epilim was to prevent another seizure which came about after his temperature shot up whil

Hi my Mom is 78yo and had her first seizure 5mths ago (we think due to the flu vaccine)and another 4wks ago, she was diagnosed with Epilepsy after her second episodeand put on Epilim. Since then she has deteriorated sign

Hi, I had one seizure and have been on epilim for nearly two years under the care of a neurologist. I went for a checkup the other day and brought up the question of going off the epilim. If it is done it has to be done really slowly, ie weaned off,

Hit the back of my head on concrete after slipping on ice. Had a full blown seizure 7 days later. This was Feb. 2010 as a procaution they put me on kappra twice a day for year. I do not like it it makes me feel like im not always in control i say and

I AM CURRENTLY TAKING LAMICTAL AND KEPPRA.I STARTED TAKING WITH KEPPRA WITH NO RESULTS IN SEIZURE CONTROL. MY DOCTOR THEN ADDED LAMICTAL DOSAGE WAS200MG A DAY.MY SEIZURES HAVE BECOME MUCH WORSE STARTING WITH THE AURAS. tHEY USED T

SEIZURE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy of Intravenous Levetiracetam in Neonatal Seizures
Condition: Neonatal Seizures
Interventions: Drug: Intravenous levetiracetam;   Drug: Intravenous phenobarbital
Outcome Measures: To determine the efficacy of intravenous LEV in terminating neonatal Seizures when given as first line therapy compared to phenobarbital;   To obtain dose escalation data by studying the additional efficacy of a further dose in non responders.;   To evaluate the benefit of remote EEG monitoring;   Evaluation of the accuracy of neonatal Seizure detection algorithm
2 Recruiting Seizure Detection and Warning System for Epilepsy Patients
Condition: Epilepsy
Intervention: Device: Night Watch Seizure Detection Device and Warning System
Outcome Measures: Primary outcome is accuracy of device to detect GTC Seizures when compared to video EEG.;   Comparison of study device to self reporting of Seizures using a Seizure diary.
3 Recruiting Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures
Condition: Nonconvulsive Electrographic Seizures
Interventions: Drug: Brivaracetam intravenous solution;   Drug: Brivaracetam oral tablets;   Drug: Phenytoin intravenous solution;   Drug: Phenytoin oral tablets
Outcome Measures: Percentage of subjects with Seizure freedom for 12 hours starting 1 hour after the end of the last acute intravenous (iv) administration of study drug and prior to the initiation of bid (twice a day) dosing;   Percentage of subjects with Seizure freedom for 12 hours starting after the end of the last acute intravenous (iv) administration of study drug and prior to the initiation of bid (twice a day) dosing;   Time to achievement of 12 hours of Seizure freedom relative to the start of the first acute intravenous (iv) administration;   Time to achievement of 12 hours of Seizure freedom relative to the start of the last acute intravenous (iv) administration that occurred prior to the initiation of bid (twice a day) dosing;   Percentage of subjects requiring a second acute intravenous (iv) administration between 15 minutes to 12 hours after first acute iv administration;   Time to first onset of Seizure cessation relative to the start of the first acute intravenous (iv) administration
4 Recruiting Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures
Conditions: Epilepsy;   Simple Partial Seizures;   Complex Partial Seizures;   Partial Seizures With Secondary Generalization
Intervention: Drug: Remegal
Outcome Measures: Seizure Frequency Reduction;   Number of Seizure's-Free Days;   CGI;   PGI;   QOLIE
5 Unknown  Safety and Feasibility of Using Epicall for Monitoring Pre-Seizure Biomarkers
Condition: Seizure
Intervention: Device: Epicall
Outcome Measures: Lack of adverse events;   Epicall feasibility for monitoring pre-Seizure biomarkers
6 Recruiting Phase 2 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures, With Long-term Open-label Extension
Condition: Drug Resistant Partial Onset Seizure
Interventions: Drug: ganaxolone;   Drug: Placebo
Outcome Measures: Percentage change in Seizure frequency per 28 days in the double blind period relative to baseline;   Change in Seizure frequency per 28 days;   Proportion of responders experiencing a ≥50% reduction from baseline to the end of the period, in total partial Seizure frequency per 28 days;   Proportion of Seizure free subjects;   Clinical Global Impression of change;   Patient Global Impression of change;   Change in the number of Seizure-free days
7 Not yet recruiting A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
Condition: Partial Onset Seizures
Interventions: Drug: Pregabalin Dose Level 1;   Drug: Pregabalin Dose Level 2;   Drug: Placebo
Outcome Measures: Percent reduction of 24 hour Seizure rate for all partial onset Seizures relative to placebo during the double-blind assessment phase.;   Responder rate, defined as the proportion of subjects who had at least a 50% reduction in 24 hour partial onset Seizure rate.
8 Not yet recruiting Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.
Condition: Depressive Disorder
Interventions: Device: Magnetic Seizure therapy;   Device: Electroconvulsive therapy
Outcome Measure: Hamilton Rating Scale for Depression, 24-item (HRSD-24)
9 Recruiting Respiratory Physiology in Children With Febrile Seizures.
Conditions: Febrile Illness in Children;   Seizures, Febrile
Intervention:
Outcome Measures: Change of transcutaneous pCO2 per change of body temperature [mmHg/degree C];   Change of respiratory rate per change of body temperature [1/sec * degree C];   Change of transcutaneous pCO2 per change of respiratory rate [mmHg * sec]
10 Recruiting Pilot Study of Bumetanide for Newborn Seizures
Condition: Seizures
Interventions: Drug: Bumetanide;   Other: Normal Saline
Outcome Measures: The primary outcome is determination of the pharmacokinetics and safety of bumetanide in newborns with refractory Seizures.;   A secondary outcome is determination of the feasibility of a novel study design to test antiepileptic drugs to treat neonatal Seizures caused by acute hypoxic-ischemic encephalopathy in a clinical trial.
11 Recruiting A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
Condition: Generalized Tonic Clonic Seizures
Interventions: Drug: Pregabalin Dose Level 1;   Drug: Pregabalin Dose Level 2;   Drug: Placebo
Outcome Measures: Percent reduction of 28 day Seizure rate for all PGTC Seizures relative to placebo during the double blind assessment phase.;   Responder rate, defined as the proportion of subjects who had at least a 50% reduction in 28 day PGTC Seizure.
12 Recruiting A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Outcome Measures: SAE's (serious adverse event) and AE's (adverse events);   Vital signs;   Physical exams to assess change from baseline for physical state of limbs, torso, and organs and Neurological exams to assess change from baseline for measures of peripheral and central nervous system function.;   Clinical laboratory data (hematology , chemistry, urinalysis;   Electrocardiograms;   Suicidality assessments;   Cognitive testing
13 Unknown  Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study
Condition: Seizure, Alcohol Related
Intervention: Drug: levetiracetam
Outcome Measure: Decreased Seizures
14 Recruiting A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin add-on therapy
Outcome Measures: Log transformed (loge) 28 day Seizure rate for all partial onset Seizures collected during the 12 week double-blind treatment phase, reported as "percent reduction in Seizures" relative to placebo.;   Responder Rate, defined as subjects who have a 50% or greater reduction in partial Seizure rate from baseline during the double-blind treatment phase.
15 Unknown  Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
Conditions: Epilepsy;   Partial Seizures
Interventions: Drug: Levetiracetam;   Drug: Placebo
Outcome Measures: Partial onset Seizure frequency per week.;   Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and ECG and laboratory tests results.;   Proportions of response between the groups of treatment. (Responders defined as number of patients with at least 50% reduction in the number of weekly partial Seizures);   Percentage reduction from baseline in partial Seizure frequency of days a week.;   Proportion of response between the groups of treatment. (Responders defined as number of subjects with at least 50% reduction in the number of days per week with partial Seizures);   Proportion between the groups of treatment without any kind of Seizures. (Seizure free)
16 Recruiting Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
Conditions: Epilepsy;   Partial Seizures
Interventions: Drug: Levetiracetam;   Drug: Carbamazepine
Outcome Measures: Proportion of subjects remaining Seizure free during the 6-months Evaluation Period;   Proportion of subjects retained in the study for the duration of the period covering the Up Titration Period, Stabilization Period, and Evaluation Period;   Time to first Seizure or discontinuation due to an Adverse Event (AE) / Lack of Efficacy (LOE) during the Evaluation Period;   Time to first Seizure during the Evaluation Period;   Time to first Seizure during the period covering the Up Titration Period, Stabilization Period, and Evaluation Period from the first dose of study drug
17 Recruiting Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures
Condition: Nonconvulsive Seizures
Interventions: Drug: Lacosamide - 'Crossover';   Drug: Fosphenytoin - 'crossover'
Outcome Measures: Percentage of subjects who experience no NCSs for 24 hours following treatment with LCM vs. fPHT, as measured by continuous electroencephalography (cEEG) monitoring.;   Percentage of subjects who require a rebolus of the initial antiepileptic drug (AED) to control NCSs in the LCM vs fPHT arms.;   Percentage of subjects who require a second AED to control NCSs.;   Percent change in Seizure time (defined as the number of minutes of electrographic Seizure (ESz) activity per hour) before treatment and at the end of the first treatment arm.;   Percent change in Seizure time (defined as the number of minutes of ESz activity per hour) before treatment and at the end of the second treatment arm.;   Time from bolus to time of the end of the last Seizure for both first (initial bolus/rebolus)and second (crossover bolus/rebolus) treatment arms.;   Frequency of predefined adverse events (AEs) in the LCM vs fPHT arms.;   Percentage of subjects in whom study drug is withdrawn early;   Days in the intensive care unit/hospital from start of treatment in the LCM vs fPHT arms.;   Functional status as measured by the Functional Disability Scale at Day 7 to 9 postrandomization and Day 30 post-randomization in the LCM vs fPHT arms.;   Percentage of all subjects who have had a Seizure, are on AED therapy, and are alive/dead at the 6-, 12-, and 24-month post-randomization follow-ups.
18 Recruiting Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder
Conditions: Depressive Disorder;   Schizophrenia;   Schizoaffective Disorder;   Obsessive-Compulsive Disorder
Intervention: Device: Magnetic Seizure Therapy (MagPro MST)
Outcome Measures: Score on rating scale that corresponds to diagnosis: i) Hamilton Rating Scale for Depression, 24-item (HRSD-24); or ii) Yale-Brown Obsessive Compulsive Scale (Y-BOCS); or iii) Brief Psychiatric Rating Scale (BPRS);   Score on rating scale that corresponds to diagnosis: i) HRSD-24; or ii) Y-BOCS; or iii) BPRS;   Cognitive Functioning;   Neuroimaging (brain structure and activity)
19 Recruiting A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
Condition: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: Drug: RAD001;   Drug: Placebo
Outcome Measures: European Medicine Agency (EMA): Response rate;   Food & Drug Administration (FDA): Percentage reduction in partial onset Seizure frequency;   Seizure free rate;   Proportion of patients with at least a 25% reduction in partial onset Seizure frequency;   Categorical variable of six levels of reduction from baseline in partial-onset Seizure frequency;   Frequency of Seizure free days;   Treatment duration;   Overall Quality of Life global scores;   Sub-test scores for neurocognitive, neurodevelopmental, and neurobehavioral tests;   Percentage reduction in Seizure frequency/frequency of selected adverse events;   Pre-dose concentrations of anti-epileptic drugs (AEDs) alone and post-baseline (AEDs plus everolimus);   50% response rate from Baseline by time interval over the extension phase;   Seizure free days in partial onsent Seizure by time interval over the extension phase;   Frequency of adverse events;   Frequency of abnormal laboratory values;   Frequency of Columbia Suicide Severity Rating Scale (C-SSRS) outcomes;   Frequency of serious adverve events (SAEs) referring to a positive suicidal evaluation
20 Recruiting Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
Conditions: Adult Diffuse Astrocytoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Seizure
Interventions: Procedure: cognitive assessment;   Procedure: magnetic resonance imaging;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
Outcome Measures: NCF as measured by each of the 4 neurocognitive tests (DET, IDN, OCLT, GMLT);   Time to neurocognitive decline in patients who progress and who do not progress radiologically, as defined by the RCI-WSD;   PFS;   Radiological progression;   Effect of salvage therapy on cognitive outcomes in patients who progress;   QOL as measured by the EORTC QOL-30, EORTC QOL-BCN20, and EQ-5D;   Frequency of Seizures, evaluated using patient Seizure diary;   Molecular correlates of QOL, NCF, Seizure control, and PFS;   OS;   Symptomatic or clinical progression